NCT06937944From ClinicalTrials.govRecruiting

Efficacy and Safety of Recombinant Botulinum Toxin Type A (Eveotox) for Injection to Treat Moderate to Severe Glabellar Lines

A Phase 3 Clinical Study to Evaluate the Efficacy and Safety of Recombinant Botulinum Toxin Type A for Injection (Eveotox) Compared With a Single Treatment of Botox and Placebo,and Repeated Treatment of Eveotox in Moderate to Severe Glabellar Lines

Moderate to Severe Glabellar Lines

At a glance

Phase: Phase 3
Study type: Interventional
Sponsor: JHM BioPharma (Tonghua) Co. , Ltd.
Enrolment target: 669
Started: 30 April 2025
Main results due: 9 February 2026
Study sites: 15
Registry updated: 23 September 2026

Can you take part?

Ages 18 years to 65 years.
Open to any sex.
You need the condition being studied — healthy volunteers are not accepted.

These are the headline rules only. Every study has a longer list, and whether you are eligible is decided by the research team at the site — never by this page.

Read the full eligibility criteria

Inclusion Criteria:

* Male or female subjects who are between 18 to 65 years of age
* Moderate or severe glabellar lines during maximum frown based on the Investigator Global Assessment Frown Wrinkle Severity scale
* Moderate or severe glabellar lines during maximum frown based on the Patient Frown Wrinkle Severity scale
* Willing and able to follow all trial procedures, attend all scheduled visits, and successfully complete the trial

Exclusion Criteria:

* Subjects who have a history of oversensitivity to the Botulinum Toxin A type or other components of the study drug
* Subjects who have implanted any permanent materials in the glabellar area or received semi-permanent fillers within the first 2 years of screening
* Subjects with active skin infections at the injection site or systemic skin disease, which the investigator judges can affect the evaluation of efficacy or safety
* Subjects who have a history of injecting drugs similar to the study drug within 6 months prior to selection or are foreseen to use during the study period

What this study is about

In the sponsor’s own words, from the registry.

This is a Phase 3 clinical study to evaluate the efficacy, safety, and immunogenicity of single/repeated injections of Eveotox in the treatment of moderate to severe glabellar lines. The study consists of Study Part 1 (randomized double-blind controlled study) and Part 2 (open-label study). Part I is a multicenter, randomized, double-blind, single-injection, active-controlled and placebo-controlled study to evaluate the efficacy, safety, and immunogenicity of Eveotox in the treatment of moderate to severe glabellar lines; Part 2 is an open-label study to evaluate the efficacy, safety, and immunogenicity of repeated injections of Eveotox in the treatment of moderate to severe glabellar lines.

Study sites(15)

Peking Union Medical College Hospital
Beijing, Beijing Municipality, China
Recruiting
Peking University First Hospital
Beijing, Beijing Municipality, China
Recruiting
Peking University Third Hospital
Beijing, Beijing Municipality, China
Recruiting
The First Affiliated Hospital of Chongqing Medical University
Chongqing, Chongqing Municipality, China
Recruiting
The First Affiliated Hospital of Jinan University
Guangzhou, Guangdong, China
Recruiting
The Third Affiliated Hospital of Sun Yat-sen University
Guangzhou, Guangdong, China
Recruiting
The First Hospital of Hebei Medical University
Shijiazhuang, Hebei, China
Recruiting
The Third Xiangya Hospital of Central South University
Changsha, Hunan, China
Recruiting
The Affiliated Hospital of Xuzhou Medical University
Xuzhou, Jiangsu, China
Recruiting
Huashan Hospital, Fudan University
Shanghai, Shanghai Municipality, China
Recruiting
Xianyang Hospital of Yan'an University
Xianyang, Shanxi, China
Recruiting
West China Hospital, Sichuan University
Chengdu, Sichuan, China
Recruiting
Tianjin Medical University General Hospital
Tianjin, Tianjin Municipality, China
Recruiting
Affiliated Hangzhou First People's Hospital, School of Medicine, Westlake University
Hangzhou, Zhejiang, China
Recruiting
Zhejiang Provincial People's Hospital
Hangzhou, Zhejiang, China
Recruiting

Showing 15 of 15 sites. 15 of the 15 sites on this study are recruiting right now — a site can stop enrolling while the study as a whole is still open.

Source: ClinicalTrials.gov record NCT06937944. Trialion does not run this study, is not paid to refer anyone to it, and cannot enrol you. Eligibility is always decided by the research team at the site.

Not the right study?

Answer three questions and see the studies recruiting near you, in plain language.

Find a study for me